Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
WuXi Biologics (Cayman) Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
WXXWY
Over the counter
8731
www.wuxibiologics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for WuXi Biologics (Cayman) Inc.
WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization
- May 19th, 2026 11:44 pm
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
- May 12th, 2026 9:33 pm
Assessing WuXi Biologics (SEHK:2269) Valuation After Recent Share Price Weakness
- May 11th, 2026 2:11 am
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
- Apr 29th, 2026 6:30 am
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
- Apr 24th, 2026 5:03 am
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
- Apr 23rd, 2026 12:14 am
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
- Apr 16th, 2026 11:30 pm
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
- Apr 14th, 2026 8:39 pm
Assessing WuXi Biologics (SEHK:2269) Valuation After Choppy Returns And An Undervalued Narrative
- Apr 9th, 2026 9:13 am
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
- Mar 29th, 2026 11:33 pm
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
- Mar 25th, 2026 4:22 am
WuXi Biologics Reports Record 2025 Annual Results
- Mar 24th, 2026 5:44 am
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
- Mar 21st, 2026 7:30 pm
WuXi Biologics Awards Win And Earendil Deal Viewed Against Valuation
- Mar 15th, 2026 11:04 pm
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
- Mar 12th, 2026 9:09 pm
Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs
- Mar 12th, 2026 3:00 am
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics
- Mar 2nd, 2026 2:09 am
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
- Mar 1st, 2026 8:21 pm
Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story
- Feb 14th, 2026 11:09 pm
Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential
- Feb 13th, 2026 2:19 am
Scroll